177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma
ChemBioChem · 2025
DOI: 10.1002/cbic.202400579 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Yadong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610000, China. Hauptthemen laut MEDLINE: Indoles, Polymers, Glioma, Lutetium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Joint Innovation Fund of Sichuan University and Nuclear Power Institute of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Radionuclide therapy is expected to be a powerful tool for glioma treatment. Here, we introduced a novel nuclear nanomedicine based on polydopamine (PDA), incorporating fibroblast activation protein inhibitor (FAPI) and macrocyclic chelator (DOTA) for specific cancer targeting and 177 Lu labeling. The synthesized nanoradiopharmaceutical, 177 Lu‐DOTA‐PEG‐PDA‐FAPI, exhibits good stability in serum, saline and PBS over 5 days. 177 Lu‐DOTA‐PEG‐PDA‐FAPI shows efficient specific uptake and internalization when incubated with U87MG cells. In vivo distribution visualized prominent accumulation and long retention ability of 177 Lu‐DOTA‐PEG‐PDA‐FAPI at tumor sites after local administration. Moreover, 177 Lu‐DOTA‐PEG‐PDA‐FAPI has satisfactory antitumor ability without apparent toxic and side effects observed from therapy assay and H&E staining. This study highlights the feasibility of using PDA as a nanocarrier for glioma endoradiotherapy by targeting fibroblast activation protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610000, China.
- Sichuan Engineering Research Center for Radioactive Isotope, National Engineering Research Center for Isotopes and Pharmaceuticals, Nuclear Power Institute of China, Chengdu, 610000, China.
ORCID-Profile: Ning Liu
Förderung
- National Natural Science Foundation of China
- Joint Innovation Fund of Sichuan University and Nuclear Power Institute of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, Y., Qiu, L., Ye, T., Tan, F., Lyu, J., Li, F., Sun, Z., Yang, Y., Zhang, J., Liu, N., & Liao, J. (2025). 177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma. ChemBioChem. https://doi.org/10.1002/cbic.202400579
Vancouver
Wang Y, Qiu L, Ye T, Tan F, Lyu J, Li F, et al. 177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma. ChemBioChem. 2025. doi:10.1002/cbic.202400579
BibTeX
@article{Wang2025,
author = {Wang, Yadong and Qiu, Long and Ye, Tianzhen and Tan, Fuyuan and Lyu, Jie and Li, Feize and Sun, Zhizhong and Yang, Yuanyou and Zhang, Jinsong and Liu, Ning and Liao, Jiali},
title = {177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma},
journal = {ChemBioChem},
year = {2025},
doi = {10.1002/cbic.202400579}
}
EUVIMED